Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MiSaver will be administered via peripheral intravenous injection. Based on dosage, the experimental group will be divided into two subgroups: 0.5 × 10⁷ or 1.6 × 10⁷ nucleated cells per kilogram of patient body weight.”In the company’s words, NCT07134712 on ClinicalTrials.gov
- Tested for
- Acute Myocardial Infarction (AMI)
- Main trialPhase 2
- “This trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improvement in left ventricular function of the heart following the administration of MiSaver, as well as to determine the safety of using stem cell therapy in these patients. This trial will employ a single-blind design (subject-blinded), meaning that the participants will not be aware of whether they are receiving MiSaver…”In the company’s words, NCT07134712 on ClinicalTrials.gov
- Other names
- stem cells · Cord Blood Nucleated cells
Other drugs for Acute Myocardial Infarction (AMI)
- InclisiranNovartis · Phase 3
- MLC1501Moleac Pte Ltd. · Phase 2/3
- ZiltivekimabNovo Nordisk · Phase 3
- ClazakizumabCSL Behring · Phase 2/3
- PelacarsenNovartis · Phase 3
- PacibekitugNovartis · Phase 3
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Dec 2027 | Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II | |
| Phase 1/2Completed | 4 May 2023 | MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026